Diabetic ketoacidosis as a complication of immune checkpoint inhibitor therapy
Nathan L. Haas,
Jordan Sell,
Benjamin S. Bassin,
Frederick K. Korley
Affiliations
Nathan L. Haas
Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA; Division of Critical Care, Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA; The Max Harry Weil Institute for Critical Care Research and Innovation, Ann Arbor, MI, USA; Corresponding author. Michigan Medicine, Department of Emergency Medicine, Taubman Center, B1354 1500 E Medical Center Dr, SPC 5303 Ann Arbor, MI, 48109-5305, USA.
Jordan Sell
Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA
Benjamin S. Bassin
Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA; Division of Critical Care, Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA; The Max Harry Weil Institute for Critical Care Research and Innovation, Ann Arbor, MI, USA
Frederick K. Korley
Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA; The Max Harry Weil Institute for Critical Care Research and Innovation, Ann Arbor, MI, USA
Background: Diabetic ketoacidosis (DKA) is a rare complication of immune checkpoint inhibitor (ICI) therapy, a treatment used for many malignancies. Case reports: We present two cases of adults, one without a prior history of diabetes, presenting to the Emergency Department (ED) with DKA induced by ICI therapy.Why should an emergency physician be aware of this? The emergency physician should be aware of the spectrum of complications associated with ICI therapy, and should remain vigilant in patients presenting with symptoms of DKA and/or unexplained elevated anion gap metabolic acidosis, as DKA in patients without a history of diabetes mellitus can go unrecognized.
